ArticleHealth science reports2026
Hodgkin Lymphoma With Liver Involvement (Diagnostic, Therapeutic Difficulties, and Literature Review): A Retrospective Cohort Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hodgkin Lymphoma With Liver Involvement (Diagnostic, Therapeutic Difficulties, and Literature Review): A Retrospective Cohort Study.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: In classical Hodgkin lymphoma liver involvement occurs in 5%-8%, ranging from mild dysfunction to acute liver failure. Recognition and treatment of advanced cases are challenging due to rapid progression and limited use of therapies. Methods: We analyzed the data of 250 Hodgkin lymphoma patients; 9 had liver involvement, one in the form of acute liver failure. Results: Laboratory findings showed elevations of cholestatic enzymes, lactate dehydrogenase and haemostatic changes. PET/CT showed solo or multiple active areas in the liver and diffuse elevated standard uptake value in the patient with acute liver failure. In six cases ABVD/EBVD, in two brentuximab vedotin+AVD were used. Four patients achieved complete remission, four were relapsed or refractory, three of them died later. Brentuximab vedotin was started for the patient with acute liver failure, but she died in 2 days. Autopsy confirmed a Hodgkin-infiltrated liver structure. Conclusion: Liver involvement has a negative impact on prognosis; however, early diagnosis and immediate initiation of therapy improve liver function. PET/CT can be a practical tool to support diagnosis and monitor response to therapy in patients where liver biopsy is not possible or does not contribute significantly to clinical management. With preserved liver function, ABVD is an effective treatment option, while with worsening liver function, brentuximab vedotin can be a safe alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.